Orthocell Ltd · ASX:OCC
Orthocell — WA Life Sciences Broker Meets Biotech 2026
26 slides from Orthocell's conference presentation, Mar 31, 2026
Slide 1: ASX Announcement: Orthocell to present at Broker Meets Biotech
ASX Announcement Investor Presentation Orthocell Ltd to present at Broker Meets Biotech Perth, Australia, 31 March 2026: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to release a copy of the presentation to be delivered by Managing Director Paul
Slide 2: Forward Looking Statement
products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.
Slide 3: Investor Presentation – Broker Meets Biotech
For personal use only Investor Presentation Broker Meets Biotech 31 March 2026
Slide 4: Disclaimer
Disclaimer For personal use only This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, representations contained in this presentation, and they do not accept any liability or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy whatsoever (i
Slide 5: Commercialisation of Remplir is on-track
Commercialisation of Remplir is on-track Australian medical technology company with growing international revenue and US market launch of its flagship nerve repair product, Remplir For personal use only Fully funded US strategy US market share1 to and investing in growth is on-track reach cash break
Slide 6: Strategy and Focus
For personal use only Strategy and Focus
Slide 7: Orthocell three-year vision
Orthocell three-year vision For personal use only Establish Orthocell as a global regenerative medicine leader through disciplined growth, Business operational excellence and a sustainable product pipeline, achieving ASX 300 inclusion goal Win in the Accelerate growth Scale a global collagen Expand
Slide 8: Focus in FY26
Focus in FY26 For personal use only Gaining market Strategic Asia Complete UK and EU Recruit specialist access and growing expansion focused on launch planning talent to deepen the customer base high-return markets post-Q2 submission expertise and enable of Remplir in the US for FY27 entry scalable
Slide 9: Continued revenue growth
Continued revenue growth 1 We have maintained constant growth over the last three halves, driven by device sales For personal use only Total Revenue by Half (A$M) CHGR2 +21% 6.2 5.0 4.2 3.5 2H FY24 1H FY25 2H FY25 1H FY26 Orthocell | Investor Presentation Broker Meets Biotech | March 2026 7 1. Reven
Slide 10: Gaining market access
For personal use only Gaining market access US update and growing the customer base of
Slide 11: Nerve repair, made SMRT
Nerve repair, made SMRT Collagen nerve wrap used in the repair of peripheral nerve injuries - reclaiming patients touch, movement and function. For personal use only Guiding predictable outcomes in peripheral nerve repair Mimics the natural Creates an optimal Easy to handle and Protects the repair e
Slide 12: US Peripheral Nerve Repair Trends
US Peripheral Nerve Repair Trends Suturing is still the most commonly performed procedure and considered to be the “gold standard” technique for peripheral nerve repair For personal use only Over 700,0001 peripheral nerve repair procedures in the US per year, 90% undertaken using suture only method.
Slide 13: Significant US Market Opportunity
Significant US Market Opportunity Orthocell has commenced commercial distribution into an estimated US$1.6 billion total addressable nerve repair market1 in the US alone For personal use only Remplir is not seeking to replace a current dominant market incumbent. Devices are only used in ~10% of proc
Slide 14: Pathway to US commercial success
Pathway to US commercial success Progress measures are on-track or ahead of target Requirements post FDA approval1 Progress measures2 For personal use only 1. Regulatory & Licensing State licensing to allow clinical use of the product Approved to sell in 453 states 7 direct team members hired Establ
Slide 15: Financials
For personal use only Financials Path to breakeven and performance to date
Slide 16: Path to profitability (Cashflow Breakeven)
Path to profitability (Cashflow Breakeven) Breakeven2 is achieved at 5,000–6,000 procedures in the US, requiring ~300-400 active surgeons — a number already accessible through the current VAC pipeline For personal use only Breakeven Breakeven Profile (1% of market1) <1% U.S. market share required to
Slide 17: US performance since launch
US performance since launch Exceptional early growth since the first sale of Remplir on 26th June 2025 (9 months) For personal use only US Remplir Hospitals Cumulative by US Remplir Surgeons Cumulative by US Remplir Unit Sales by Quarter Quarter Quarter 521 481 110 - 1201 +263% +380% 84 +273% 21 19
Slide 18: AU/NZ Performance since launch
AU/NZ Performance since launch Significant growth achieved since launch, with near 100% YOY growth, 314 surgeons and 224 hospitals For personal use only Cumulative Unit Sales1 Unit Sales1 1,000 CQGR2 5,500 +40% 900 5,000 4,500 800 4,000 700 3,500 600 3,000 500 2,500 400 2,000 300 1,500 200 1,000 100
Slide 19: Promising New Application for Remplir in Prostate Cancer Surgery
Promising New Application for in Prostate Cancer Surgery Surgeons are using Remplir in prostate surgery to preserve nerve function and improve functional recovery. Potential significant expansion of the Total Addressable Market. Initial patient data expected 2H CY26. For personal use only • Australi
Slide 20: Investing in growth
For personal use only Investing in growth US focus and expanding manufacturing capacity
Slide 21: Focussed activities through to December 2026
Focussed activities through to December 2026 People Driving near-term revenue growth through disciplined execution, enabled by a team with proven track record For personal use only John Walker Phil Edmondson Kevin Leach Sales Medical Education Marketing • On-board Regional Sales Director roles and C
Slide 22: Manufacturing expansion – stage 1
Manufacturing expansion – stage 1 Manufacturing Planned capacity upgrades are in place to deliver the volumes estimated and reduce the cost of sale For personal use only Stage 1 expansion Secure and reliable capital approved supply chain • $5–5.5M investment to expand the • Manufacturing upgrades wi
Slide 23: Investment highlights
Investment highlights For personal use only Best-in-class platform Product margins Growing International Remplir US Strategy With $49.4M2 total for Bone, Nerve and retained in-house Revenues Targeting is on-track cash reserves and a Tendon repair approved Manufacturing facility Large Under Market ac
Slide 24: Achievements and upcoming catalysts
Achievements Nerve repair, made SMRT and upcoming For personal use only catalysts1 US first surgical use Achieved US first sales Achieved Appoint further US sales team members Achieved Appoint first and second distributors in CAN Achieved Appoint exclusive distributor in HKG Achieved HK first surgic
Slide 25: Thank you for attending
For personal use only Thank you for attending
Slide 26: Authorised for release by the Board
For personal use only Authorised for release by The Board of Directors of Orthocell Limited P: +61 8 9360 2888 E: paul.anderson@orthocell.com orthocell.com
Orthocell — WA Life Sciences Broker Meets Biotech 2026 on 6ix